Clinically approved MEK and PI3K inhibitors were already used in another CS Hras G12V mouse model with only the MEK inhibitor effectively rescuing the skeletal myopathy (Tidyman et al., 2021). Here, MAP2K7 is linked to skeletal muscle disorder.